129 research outputs found

    Geotechnical properties of gullying in Tomsk Oblast

    Get PDF
    The article deals with causes, conditions and factors of gullying in Tomsk Oblast, the case of site Grodnenskaya. A nuclear-power station was planned to be constructed in Closed Administrative Territorial Unit Seversk, which led to geotechnical investigation of the area to study the geological processes developing there. The investigation included reconnaissance traverse of the area, geological and geomorphic descriptions, and sampling. The area and percentage of the territory affected by the geological processes were estimated. As a result, it was proved that the geological processes of the area are conditioned by surface water activity leading to gullying and river erosion, and by both ground water and surface water activity resulting in bog formation. It appears that gullying is caused not only by natural factors but also by technogenic ones

    On the minima and convexity of Epstein Zeta function

    Full text link
    Let Zn(s;a1,...,an)Z_n(s; a_1,..., a_n) be the Epstein zeta function defined as the meromorphic continuation of the function \sum_{k\in\Z^n\setminus\{0\}}(\sum_{i=1}^n [a_i k_i]^2)^{-s}, \text{Re} s>\frac{n}{2} to the complex plane. We show that for fixed sn/2s\neq n/2, the function Zn(s;a1,...,an)Z_n(s; a_1,..., a_n), as a function of (a1,...,an)(R+)n(a_1,..., a_n)\in (\R^+)^n with fixed i=1nai\prod_{i=1}^n a_i, has a unique minimum at the point a1=...=ana_1=...=a_n. When i=1nci\sum_{i=1}^n c_i is fixed, the function (c1,...,cn)Zn(s;ec1,...,ecn)(c_1,..., c_n)\mapsto Z_n(s; e^{c_1},..., e^{c_n}) can be shown to be a convex function of any (n1)(n-1) of the variables {c1,...,cn}\{c_1,...,c_n\}. These results are then applied to the study of the sign of Zn(s;a1,...,an)Z_n(s; a_1,..., a_n) when ss is in the critical range (0,n/2)(0, n/2). It is shown that when 1n91\leq n\leq 9, Zn(s;a1,...,an)Z_n(s; a_1,..., a_n) as a function of (a1,...,an)(R+)n(a_1,..., a_n)\in (\R^+)^n, can be both positive and negative for every s(0,n/2)s\in (0,n/2). When n10n\geq 10, there are some open subsets In,+I_{n,+} of s(0,n/2)s\in(0,n/2), where Zn(s;a1,...,an)Z_{n}(s; a_1,..., a_n) is positive for all (a1,...,an)(R+)n(a_1,..., a_n)\in(\R^+)^n. By regarding Zn(s;a1,...,an)Z_n(s; a_1,..., a_n) as a function of ss, we find that when n10n\geq 10, the generalized Riemann hypothesis is false for all (a1,...,an)(a_1,...,a_n).Comment: 27 page

    Composition and distribution of the peracarid crustacean fauna along a latitudinal transect off Victoria Land (Ross Sea, Antarctica) with special emphasis on the Cumacea

    Get PDF
    The following study was the first to describe composition and structure of the peracarid fauna systematically along a latitudinal transect off Victoria Land (Ross Sea, Antarctica). During the 19th Antarctic expedition of the Italian research vessel “Italica” in February 2004, macrobenthic samples were collected by means of a Rauschert dredge with a mesh size of 500 m at depths between 85 and 515 m. The composition of peracarid crustaceans, especially Cumacea was investigated. Peracarida contributed 63% to the total abundance of the fauna. The peracarid samples were dominated by amphipods (66%), whereas cumaceans were represented with 7%. Previously, only 13 cumacean species were known, now the number of species recorded from the Ross Sea increased to 34. Thus, the cumacean fauna of the Ross Sea, which was regarded as the poorest in terms of species richness, has to be considered as equivalent to that of other high Antarctic areas. Most important cumacean families concerning abundance and species richness were Leuconidae, Nannastacidae, and Diastylidae. Cumacean diversity was lowest at the northernmost area (Cape Adare). At the area off Coulman Island, which is characterized by muddy sediment, diversity was highest. Diversity and species number were higher at the deeper stations and abundance increased with latitude. A review of the bathymetric distribution of the Cumacea from the Ross Sea reveals that most species distribute across the Antarctic continental shelf and slope. So far, only few deep-sea records justify the assumption of a shallow-water–deep-sea relationship in some species of Ross Sea Cumacea, which is discussed from an evolutionary point of view

    Experience of the successful treatment with canakinumab of a patient with NLPC4-associated autoinflammatory syndrome with enterocolitis

    Get PDF
    The article shows the observation of rare NLPC4-associated autoinflammatory syndrome with enterocolitis and familial cold urticaria. Diagnosis is confirmed molecularly-genetically: previously not described mutation c.928C>T in the heterozygous state in NLRC4 gene is discovered by a method of the new generation sequencing. The use of a monoclonal antibody to the interleukin 1 canakinumab provided complete relief of fever and skin and intestinal symptoms in just 1 week of treatment. Later the signs of inflammation have disappeared completely; the patient’s quality of life improved and life-threatening complications were prevented. The above example demonstrates the high clinical efficacy of canakinumab in the patient with NLRC4-associated autoinflammatory syndrome and suggests promising therapeutic use of interleukin 1 blockers in such patients. There were no adverse events during canakinumab therapy

    High Efficiency of Kanakinumabum for a Patient with a Late Diagnosed Chronic Infantile Neurological Cutaneous Articular Syndrome (CINCA)

    Get PDF
    The article presents the monitoring of a severe course of CINCA/NOMID syndrome diagnosed at late stages. The use of monoclonal antibodies to IL 1 — kanakinumabum — in a patient with chronic neurological cutaneous and articular syndrome was successful: fever, cutaneous and pain syndromes were completely stopped, joint contractures decreased after one week of therapy. Laboratory parameters of the child’s disease activity (ESR and CRP) became normal after 8 weeks of treatment. Movements in the affected joints recovered completely after 24 weeks; the audiologist noted an improvement in hearing. The above clinical example demonstrates the high efficiency of kanakinumabum for a patient with chronic neurological cutaneous and articular syndrome, and shows the perspective of therapeutic application of IL 1 blocker for patients with CINCA syndrome including advanced stages of the disease. No adverse effects were noted during kanakinumabum therapy

    Conformational Stability Analyses of Alpha Subunit I Domain of LFA-1 and Mac-1

    Get PDF
    β2 integrin of lymphocyte function-associated antigen-1 (LFA-1) or macrophage-1 antigen (Mac-1) binds to their common ligand of intercellular adhesion molecule-1 (ICAM-1) and mediates leukocyte-endothelial cell (EC) adhesions in inflammation cascade. Although the two integrins are known to have distinct functions, the corresponding micro-structural bases remain unclear. Here (steered-)molecular dynamics simulations were employed to elucidate the conformational stability of α subunit I domains of LFA-1 and Mac-1 in different affinity states and relevant I domain-ICAM-1 interaction features. Compared with low affinity (LA) Mac-1, the LA LFA-1 I domain was unstable in the presence or absence of ICAM-1 ligand, stemming from diverse orientations of its α7-helix with different motifs of zipper-like hydrophobic junction between α1- and α7-helices. Meanwhile, spontaneous transition of LFA-1 I domain from LA state to intermediate affinity (IA) state was first visualized. All the LA, IA, and high affinity (HA) states of LFA-1 I domain and HA Mac-1 I domain were able to bind to ICAM-1 ligand effectively, while LA Mac-1 I domain was unfavorable for binding ligand presumably due to the specific orientation of S144 side-chain that capped the MIDAS ion. These results furthered our understanding in correlating the structural bases with their functions of LFA-1 and Mac-1 integrins from the viewpoint of I domain conformational stability and of the characteristics of I domain-ICAM-1 interactions

    The adaptive potential of North American subtype H7N2 avian influenza viruses to mammals

    Get PDF
    Introduction. H7 subtype avian influenza viruses causing severe epizootics among birds are phylogenetically different in the Eastern and Western hemispheres. Numerous human infections caused by these viruses in the Eastern hemisphere indicate that H7 viruses can overcome the interspecies barrier and pose a potential threat of a new pandemic.The H7N2 viruses with deletion of amino acids 221–228 (H3 numbering) in hemagglutinin (HA) had been circulating among poultry in the Western Hemisphere during 1996–2006, and had once again been detected in 2016 in an animal shelter, where they caused cat diseases. The objective of this study is to elucidate the mechanism of adaptation to mammals of North American H7N2 influenza viruses with deletion in HA. Materials and methods. The A/chicken/New Jersey/294598-12/2004 (H7N2) virus was adapted to mice by the lung passages. Complete genomes of original and mouse-adapted viruses were analyzed. The receptor specificity and thermostability of viruses, HA activation pH and virulence for mice were determined. Results. The non-pathogenic H7N2 avian influenza virus became pathogenic after 10 passages in mice. Amino acid substitutions occurred in five viral proteins: one in PB2 (E627K), NA (K127N), NEP (E14Q), four in HA and six in NS1. Mutations in HA slightly changed receptor specificity but increased the pH of HA activation by 0.4 units. The NS1 protein undergone the greatest changes in the positions (N73T, S114G, K118R, G171A, F214L and G224R), where amino acid polymorphisms were observed in the original virus, but only minor amino acid variants have been preserved in the mouse adapted variant. Conclusion. The results show that H7N2 viruses have the potential to adapt to mammals. The increase in virulence is most likely due to the adaptive E627K mutation in PB2 and possibly in HA

    ДИАГНОСТИКА СИНДРОМА КАВАСАКИ И ОПЫТ ПРИМЕНЕНИЯ ИММУНОГЛОБУЛИНА НОРМАЛЬНОГО ЧЕЛОВЕЧЕСКОГО ДЛЯ ВНУТРИВЕННОГО ВВЕДЕНИЯ

    Get PDF
    The article presents a case of late diagnosis of cutaneomucosal lymphonodular syndrome (Kawasaki syndrome). The child featured fever, mucosal lesion (conjunctivitis, stomatitis), rash, thick edemas on arms and feet, arthritis and coronaritis. Initial therapy proved ineffective. Pathogenetic therapy, which proved to be rather effective, was prescribed after diagnosis was confirmed. The authors present a case of successful use of normal human immunoglobulin for intravenous injections in the dose of 2 g/kg of body weight per course in combination with acetylsalicylic acid in the dose of 80 mg/kg per day. Body temperature decreased down to subfebrile figures and foot pain attenuated as early as after 1 day of treatment. Fever, rash, stomatitis and conjunctivitis terminated, edemas of limbs and arthritic manifestations attenuated considerably and laboratory parameters of disease activity normalized after 1 week (ESR and CRP). Inflammation of coronary arteries terminated after 3 weeks. No adverse events in the setting of immunoglobulin therapy were observed.  В статье представлен случай поздней диагностики слизисто-кожного лимфонодулярного синдрома (синдрома Кавасаки). У ребенка отмечались лихорадка, поражение слизистых оболочек (конъюнктивит, стоматит), сыпь, плотные отеки кистей и стоп, артрит, коронарит. Инициальная терапия оказалась неэффективна. При подтверждении диагноза назначена патогенетическая терапия с хорошим эффектом. Авторы представляют успешное применение иммуноглобулина нормального человеческого для внутривенного введения в дозе 2 г/кг массы тела на курс в сочетании с ацетилсалициловой кислотой в дозе 80 мг/кг в сут. Уже через 1 сут лечения температура у ребенка снизилась до субфебрильных цифр, уменьшились боли в стопах. Через 1 нед купировались лихорадка, сыпь, стоматит, конъюнктивит; значительно уменьшились отеки конечностей и явления артрита, нормализовались лабораторные показатели активности болезни (СОЭ и СРБ). Через 3 нед купировалось воспаление в коронарных артериях. Нежелательных явлений на фоне терапии иммуноглобулином у ребенка не отмечалось.

    Высокая эффективность канакинумаба у пациента с поздно диагностированным криопиринассоциированным синдромом (синдром CINCA)

    Get PDF
    The article presents the monitoring of a severe course of CINCA/NOMID syndrome diagnosed at late stages. The use of monoclonal antibodies to IL 1 — kanakinumabum — in a patient with chronic neurological cutaneous and articular syndrome was successful: fever, cutaneous and pain syndromes were completely stopped, joint contractures decreased after one week of therapy. Laboratory parameters of the child’s disease activity (ESR and CRP) became normal after 8 weeks of treatment. Movements in the affected joints recovered completely after 24 weeks; the audiologist noted an improvement in hearing. The above clinical example demonstrates the high efficiency of kanakinumabum for a patient with chronic neurological cutaneous and articular syndrome, and shows the perspective of therapeutic application of IL 1 blocker for patients with CINCA syndrome including advanced stages of the disease. No adverse effects were noted during kanakinumabum therapy.статье представлено наблюдение диагностированного в поздние сроки тяжелого течения криопиринассоциированного синдрома (синдром CINCA/NOMID). Описано успешное применение моноклональных антител к IL 1 — канакинумаба — у пациента с хроническим неврологическим кожным и суставным синдромом: уже через 1 нед терапии полностью купировались лихорадка, кожный и болевой синдромы, уменьшились контрактуры в суставах. Через 8 нед лечения у ребенка нормализовались лабораторные показатели активности болезни (СОЭ и СРБ). Через 24 нед полностью восстановились движения в пораженных суставах; сурдологом отмечено улучшение слуха. Приведенный клинический пример демонстрирует высокую эффективность канакинумаба у больного хроническим неврологическим кожным и суставным синдромом и свидетельствует о перспективности терапевтического применения блокатора IL 1 у пациентов с криопиринассоциированным синдромом, в том числе на поздних стадиях заболевания. Нежелательных явлений на фоне терапии канакинумабом не отмечалось

    Опыт успешного лечения канакинумабом пациентки с NLPC4-ассоциированным аутовоспалительным синдромом с энтероколитом

    Get PDF
    The article shows the observation of rare NLPC4-associated autoinflammatory syndrome with enterocolitis and familial cold urticaria. Diagnosis is confirmed molecularly-genetically: previously not described mutation c.928C>T in the heterozygous state in NLRC4 gene is discovered by a method of the new generation sequencing. The use of a monoclonal antibody to the interleukin 1 canakinumab provided complete relief of fever and skin and intestinal symptoms in just 1 week of treatment. Later the signs of inflammation have disappeared completely; the patient’s quality of life improved and life-threatening complications were prevented. The above example demonstrates the high clinical efficacy of canakinumab in the patient with NLRC4-associated autoinflammatory syndrome and suggests promising therapeutic use of interleukin 1 blockers in such patients. There were no adverse events during canakinumab therapy.Представлено наблюдение редкого NLPC4-ассоциированного аутовоспалительного синдрома с энтероколитом и семейной холодовой крапивницей. Диагноз подтвержден молекулярно-генетически: методом секвенирования нового поколения обнаружена ранее не описанная мутация c.928C>T в гетерозиготном состоянии в гене NLRC4. Применение моноклонального антитела к интерлейкину 1 канакинумаба уже через 1 нед лечения обеспечило полное купирование лихорадки, кожного и кишечного синдрома. В дальнейшем зафиксировано полное исчезновение признаков воспаления, повышение качества жизни больной, а также предотвращение развития жизнеугрожающих осложнений. Приведенный клинический пример демонстрирует высокую эффективность канакинумаба у больной с NLRC4-ассоциированным аутовоспалительным синдромом и свидетельствует о перспективности терапевтического применения блокатора интерлейкина 1 у таких пациентов. Нежелательных явлений на фоне терапии канакинумабом не зарегистрировано
    corecore